Caveolae with serotonin and NMDA receptors as promising targets for the treatment of Alzheimer’s disease DOI

Moeka Nakashima,

Naoko Suga,

Akari Fukumoto

и другие.

International Journal of Physiology Pathophysiology and Pharmacology, Год журнала: 2024, Номер 16(5), С. 96 - 110

Опубликована: Янв. 1, 2024

Alzheimer's disease is the most general type of cognitive impairments. Until recently, strategies that prevent its clinical progression have remained more elusive. Consequently, research direction should be for finding effective neuroprotective agents. It has been suggested oxidative stress, mitochondrial injury, and inflammation level might lead to brain cell death in many neurological disorders. Therefore, several autophagy-targeted bioactive compounds may promising candidate therapeutics prevention damage. Interestingly, some risk genes are expressed within cells, which linked cholesterol metabolism, lipid transport, endocytosis, exocytosis and/or caveolae formation, suggesting a fruitful therapeutic target improve This review would highlight latest advances technologies treatment disease. In particular, paradigm serotonin N-methyl-d-aspartate (NMDA) receptors agonist/antagonist structure possibly impairment. cellular membrane biophysics our understanding pathology dysfunction associated with Here, this purpose therapy open potential move care toward disease-modifying certain benefits patients.

Язык: Английский

Deciphering the Functions of Raphe–Hippocampal Serotonergic and Glutamatergic Circuits and their Deficits in Alzheimer’s Disease DOI Open Access
Wanting Yu, R Zhang,

Aosheng Zhang

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(3), С. 1234 - 1234

Опубликована: Янв. 30, 2025

Subcortical innervation of the hippocampus by raphe nucleus is essential for emotional and cognitive control. The two major afferents from to originate serotonergic glutamatergic neurons, which control hippocampal inhibitory network, theta activity, synaptic plasticity have been extensively explored in growing body literature, whereas those circuits received little attention. Notably, both between are disrupted Alzheimer's disease (AD), may contribute initiation progression behavioral psychological symptoms dementia. Thus, deciphering mechanism underlying abnormal raphe-hippocampal AD crucial prevent dementia-associated symptoms. In this review, we summarize anatomical, neurochemical, electrophysiological diversity nuclei as well architecture circuitry. We then elucidate subcortical activity their role regulation emotion cognition. Additionally, present an overview pathogenesis analyze available therapies that can potentially be used clinically alleviate neuropsychiatric decline course.

Язык: Английский

Процитировано

0

The interaction between neurotransmitter receptor activity and amyloid-β pathology in Alzheimer's disease DOI

Yuhan Nong,

Jung Soo Kim, Jia Li

и другие.

Journal of Alzheimer s Disease, Год журнала: 2025, Номер unknown

Опубликована: Май 19, 2025

The accumulation of amyloid-β (Aβ) peptides is a hallmark Alzheimer's disease (AD). Central to AD pathology the production Aβ through amyloidogenic processing protein precursor (AβPP) by β-secretase (BACE-1) and γ-secretase. Recent studies have shifted focus from plaque deposits more toxic soluble oligomers. One significant way in which impair neuronal information influencing neurotransmitter receptor function. These receptors, including adrenergic, acetylcholine, dopamine, 5-HT, glutamate, gamma-aminobutyric acid (GABA) play crucial role regulating synaptic transmission, underlies perceptual cognitive functions. This review explores how interacts with these key receptors interactions contribute neural dysfunction AD. Moreover, we examine agonists antagonists influence pathology, offering new perspectives on potential therapeutic strategies curb progression effectively improve patients’ quality life.

Язык: Английский

Процитировано

0

Targeting the Serotonergic System in the Treatment of Neurodegenerative Diseases – Emerging Therapies and Unmet Challenges# DOI Creative Commons

Alina Brüge,

Evgeni Ponimaskin, Josephine Labus

и другие.

Pharmacological Reviews, Год журнала: 2025, Номер unknown, С. 100071 - 100071

Опубликована: Май 1, 2025

Язык: Английский

Процитировано

0

Caveolae with serotonin and NMDA receptors as promising targets for the treatment of Alzheimer’s disease DOI

Moeka Nakashima,

Naoko Suga,

Akari Fukumoto

и другие.

International Journal of Physiology Pathophysiology and Pharmacology, Год журнала: 2024, Номер 16(5), С. 96 - 110

Опубликована: Янв. 1, 2024

Alzheimer's disease is the most general type of cognitive impairments. Until recently, strategies that prevent its clinical progression have remained more elusive. Consequently, research direction should be for finding effective neuroprotective agents. It has been suggested oxidative stress, mitochondrial injury, and inflammation level might lead to brain cell death in many neurological disorders. Therefore, several autophagy-targeted bioactive compounds may promising candidate therapeutics prevention damage. Interestingly, some risk genes are expressed within cells, which linked cholesterol metabolism, lipid transport, endocytosis, exocytosis and/or caveolae formation, suggesting a fruitful therapeutic target improve This review would highlight latest advances technologies treatment disease. In particular, paradigm serotonin N-methyl-d-aspartate (NMDA) receptors agonist/antagonist structure possibly impairment. cellular membrane biophysics our understanding pathology dysfunction associated with Here, this purpose therapy open potential move care toward disease-modifying certain benefits patients.

Язык: Английский

Процитировано

1